<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451942</url>
  </required_header>
  <id_info>
    <org_study_id>HNSZLG-GE-003</org_study_id>
    <nct_id>NCT03451942</nct_id>
  </id_info>
  <brief_title>The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal</brief_title>
  <official_title>The Clinical Study of FLOT Regimen Conversion Therapy of Her-2 Negative and Single Site Metastasis Adenocarcinoma of the Stomach / Gastroesophageal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate survival benefit of surgical treatment after FLOT regimen conversion therapy of
      Her-2 Negative and single site metastasis adenocarcinoma of the stomach / gastroesophageal
      compared with chemotherapy, use relevant biomarkers to evaluate the efficacy of chemotherapy
      and seek for patients with Her-2 negative and metastatic adenocarcinoma of the stomach /
      gastroesophageal surviving benefit from surgical treatment after the FLOT regimen conversion
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>the first day of treatment to death or last survival confirm date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Tumor tissue was completely resected as a percentage of all surgical patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Adenocarcinoma of the Stomach / Gastroesophageal</condition>
  <arm_group>
    <arm_group_label>surgery group after FLOT regimen chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLOT regimen chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLOT regimen chemotherapy</intervention_name>
    <description>FLOT regimen chemotherapy</description>
    <arm_group_label>surgery group after FLOT regimen chemotherapy</arm_group_label>
    <arm_group_label>FLOT regimen chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 gastric and imaging metastases resection</intervention_name>
    <description>After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)</description>
    <arm_group_label>surgery group after FLOT regimen chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients volunteered to participate in this study and signed informed consent.

          2. Endoscopic biopsy or metastatic biopsy was confirmed to be the adenocarcinoma of the
             stomach / gastroesophageal.

          3. Her - 2 negative(Including: Her protein detection -/1+, and Her protein 2+ but FISH
             negative).

          4. Without any antitumor therapy;

          5. According to the 7th edition of AJCC, imaging (CT/MRI) confirmed that the
             adenocarcinoma of the stomach / gastroesophageal with the initial single site
             metastasis had a detectable lesion (according to the RECIST 1.1 standard); Single site
             metastasis includes: liver, spleen, pancreas, ovary, retroperitoneal lymph node
             (16a1/b2), adrenal gland, kidney;

          6. Age from 18 to 70 years.

          7. Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.

          8. Life expectancy more than 12 weeks.

          9. Histological specimens were provided for biological target detection of her-2;

         10. Surgical patients agree to undergo surgery and sign an informed consent to perform the
             risk of surgery；

         11. The main organ function meet the following criteria within 7 days before treatment:

               -  blood routine examination( No blood transfusion within 14 days)

                    1. HB≥90g/L，

                    2. ANC≥1.5×109/L，

                    3. PLT≥80×109/L；

               -  blood biochemical examination

                    1. TBIL &lt;1.5 Upper Limit Of Normal（ULN）;

                    2. ALT and AST&lt;2.5ULN(or ≤ 5×ULN in patients with liver metastases).

                    3. Cr≤1.5ULN or creatinine clearance＞60ml/min.

               -  Doppler ultrasonography: left ventricular ejection fraction (LVEF) was lower than
                  normal (50%).

         12. Female subjects of child-bearing potential should agree to use contraceptive measures
             (such as intrauterine contraceptives, contraceptives or condoms) within six months of
             the study period and the end of the study. The serum or urine pregnancy test was
             negative within 7 days prior to the study and must be non-lactation. Men subjects
             should agree to use contraceptives in the study period and within six months at the
             end of the study period.

        Exclusion Criteria:

          1. 5 years or at the same time have other malignant tumors；

          2. docetaxel or oxaliplatin and other research with chemotherapy drugs are serious
             allergy;

          3. patients with severe cachexia can not eat and can not tolerate chemotherapy and
             surgery;

          4. During the screening period, there was an unknown cause of fever before the first
             administration and the body temperature was&gt; 38.5 ° C (as judged by the investigators,
             cancer-related fever subjects could be enrolled);

          5. Patients with any severe and / or uncontrollable disease, including:

               1. Patients with hypertension who are not well controlled by antihypertensive
                  medication (systolic BP ≥150 mmHg, diastolic BP ≥100 mmHg);

               2. Myocardial ischemia or myocardial infarction with grade I or above, arrhythmia
                  (including QTc≥480 ms) and ≥2 grade congestive heart failure (New York Heart
                  Association (NYHA) classification);

               3. Severe infection that is active or uncontrollable (≥CTCAE grade 2 infection);

               4. Renal failure requires hemodialysis or peritoneal dialysis;

               5. Have a history of immunodeficiency, including HIV-positive or other acquired,
                  congenital immunodeficiency disease, or history of organ transplants;

               6. Poor glycemic control in diabetic patients (fasting blood glucose (FBG)&gt; 10 mmol
                  / L);

               7. Patients with seizures who require treatment;

          6. Currently there are gastrointestinal diseases such as intestinal obstruction
             (including incomplete intestinal obstruction) or the researchers determine the
             patients may cause gastrointestinal bleeding, perforation or obstruction;

          7. Within 4 weeks prior to enrollment, there were non-healing wounds, ulcers or
             fractures;

          8. CNS metastasis;

          9. Persons with psychiatric abuse who can not be abdicated or have mental disorders;

         10. patients who have participated in other anti-cancer drug clinical trials within 4
             weeks;

         11. According to the judgment of the researcher, there is a concomitant disease which
             seriously endangers the safety of the patient or affects the patient in completing the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>LiuYing</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

